

A3

spacer by inhalation so as to deposit said GLP-1 compound[whereto is attached a lipophilic substituent optionally via a spacer] in the lungs of the patient.

Please cancel claims 14 and 15.

REMARKS

Claims 14-15 have been canceled without prejudice or disclaimer. Therefore, claims 1-13 are pending in the present application.

This amendment is submitted to correct improper multiple dependent claims and grammar. No new matter added, and entry of the amendment is respectfully requested.

Respectfully submitted,

Date: January 10, 2001


Valeta A. Gregg, Reg. No. 35,127
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123